Triden Dosage/Direction for Use

Dietary measures initiated before therapy be continued. Response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3 months) complementary or different therapeutic measures should be considered.
Posology: Adults: The recommended dose of fenofibrate is one tablet (160 mg) to be taken once daily.
Elderly Patients: in elderly, without renal impairment, the usual adult dose is recommended.
Patient and Renal Impairment: Dosage reduction is required in patients with renal impairment. The use of dosage forms containing a lower dose of active ingredients (67 mg micronized fenofibrate capsule or 100 mg standard fenofibrate capsule) is recommended in these patients once daily.
In patients with severe chronic kidney disease, fenofibrate is not recommended.
Children: The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore, use of fenofibrate is not recommended in pediatric subjects under 18 years.
Hepatic Impairment: Fenofibrate 160 mg is not recommended for use in patients with hepatic impairment due to lack of data.
Method of Administration: Fenofibrate tablet should be swallowed whole during meal.